Leerink analyst Danielle Antalffy lowered her price target for Dexcom to $100 from $115 to reflect a broader pullback in "highflyer" valuations. The analyst believes the shares could underperform today despite a Q3 sales beat since the company now believes the non-adjunctive dosing claim is likely an early 2017 event, and after management highlighted confusion in the marketplace around competition. Additionally, Antalffy notes that the company spent more than expected, something she believes Dexcom has been fairly transparent about. The analyst reiterates an Outperform rating on the shares.